Sep 27, 2021 4:01pm EDT Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Sep 21, 2021 8:00am EDT Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
Sep 01, 2021 6:00am EDT Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
Aug 17, 2021 5:45pm EDT Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
Aug 12, 2021 7:21pm EDT Dermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public Offering
Mar 30, 2021 8:00am EDT Dermata Therapeutics Announces Initiation of a Phase 1b Trial of the Once-Weekly Topical Application of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
Jan 21, 2021 8:00am EST Dermata Therapeutics Presents Positive Data From its Phase 2b Clinical Study of DMT310 for the Treatment of Moderate to Severe Acne at the 2021 Maui Derm for Dermatologists Annual Conference
Jun 10, 2020 8:00am EDT Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
Feb 11, 2020 8:00am EST Dermata Therapeutics Announces Completion of Enrollment in a Phase 2b Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
Jul 09, 2019 8:00am EDT Dermata Therapeutics Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin
